EVAMPLIX (BALSTILIMAB) Trademark

Trademark Overview


On Monday, July 19, 2021, a trademark application was filed for EVAMPLIX (BALSTILIMAB) with the United States Patent and Trademark Office. The USPTO has given the EVAMPLIX (BALSTILIMAB) trademark a serial number of 90836060. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 1, 2023. This trademark is owned by Agenus Inc.. The EVAMPLIX (BALSTILIMAB) trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical, therapeutic and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; biological preparations, namely, antibodies for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases
evamplix (balstilimab)

General Information


Serial Number90836060
Word MarkEVAMPLIX (BALSTILIMAB)
Filing DateMonday, July 19, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 1, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 2, 2022

Trademark Statements


Description of MarkThe mark consists of a two dimensional representation of three interconnected cubes, with a single cube resting on top of two cubes to the right of the term "EVAMPLIX," which is above the term "(BALSTILIMAB)".
Goods and Servicespharmaceutical, therapeutic and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; pharmaceutical, therapeutic and biopharmaceutical preparations and substances for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases; biological preparations, namely, antibodies for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejections, and inflammatory diseases
Disclaimer with Predetermined Text"BALSTILIMAB"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 21, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAgenus Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Party NameAgenus Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events


Event DateEvent Description
Monday, May 1, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, May 1, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 27, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 2, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 2, 2022PUBLISHED FOR OPPOSITION
Wednesday, July 13, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 30, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 29, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 29, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 29, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 30, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 30, 2021NON-FINAL ACTION E-MAILED
Thursday, December 30, 2021NON-FINAL ACTION WRITTEN
Thursday, December 30, 2021PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, November 23, 2021WITHDRAWN FROM PUB - OG REVIEW QUERY
Tuesday, November 9, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 9, 2021EXAMINER'S AMENDMENT ENTERED
Tuesday, November 9, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, November 9, 2021EXAMINERS AMENDMENT E-MAILED
Tuesday, November 9, 2021EXAMINERS AMENDMENT -WRITTEN
Monday, November 8, 2021ASSIGNED TO EXAMINER
Wednesday, September 22, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, September 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED